Pharmarise Holdings Corp. (2796) AI Stock Analysis

Pharmarise Holdings Corp.

(TSE/TYO:2796)

Select Model

Rating:61Neutral

Price Target:JPY 532.00▲(6.19% Upside)

Action:reiterated

Date:09/26/26

The overall score reflects improving but still fragile fundamentals, where better cash generation and reduced debt are offset by thin, volatile profitability and non-conservative leverage; neutral-to-slightly constructive technicals add modest support, while a rich earnings multiple and only moderate dividend yield cap valuation attractiveness.

Positive Factors

Revenue GrowthThe sustained increase in revenue demonstrates durable top-line expansion over several years, indicating continued demand for the company’s pharmacy and healthcare services. A growing revenue base can support operating scale, strengthen market reach, and provide more opportunity to improve earnings as the business develops.

Negative Factors

Very Thin ProfitabilityA very small profit relative to revenue indicates that the company currently retains little earnings from each unit of sales. Thin profitability leaves limited protection against cost increases or changes in business mix and makes sustainable earnings improvement important for strengthening the company’s financial resilience.

Pharmarise Holdings Corp. (2796) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 5.76B
Dividend Yield: 2.79%
Average Volume (3M): 6,070
Price to Earnings (P/E): 59.0
Beta (1Y): 0.11
Revenue Growth: 7.64%
EPS Growth: ―
Country: Japan
Employees: 2,031
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Pharmarise Holdings Corp. Business Overview & Revenue Model

Company Description

Pharmarise Holdings Corporation predominantly oversees a chain of pharmacies that dispense prescription medications throughout Japan. These establishments fulfill prescriptions provided by medical facilities, offering vital pharmaceutical services to...

Pharmarise Holdings Corp. Financial Statement Overview

Summary

Financial performance is mixed but improving: revenues and cash generation are solid and debt has been reduced, yet margins remain thin, profitability volatile, and leverage still meaningful.

Income Statement

58Neutral

Balance Sheet

64Positive

Cash Flow

72Positive

Financial statement breakdown
Breakdown	TTM	May 2025	May 2024	May 2023	May 2022	May 2021
Income Statement
Total Revenue	70.00B	69.51B	63.51B	54.47B	52.03B	51.61B
Gross Profit	8.62B	8.64B	8.20B	7.89B	7.50B	7.42B
EBITDA	2.50B	2.58B	1.68B	1.38B	2.33B	2.69B
Net Income	95.00M	113.00M	-368.00M	-351.00M	333.00M	448.00M
Balance Sheet
Total Assets	31.22B	32.68B	31.99B	29.54B	23.46B	23.78B
Cash, Cash Equivalents and Short-Term Investments	2.94B	6.01B	4.91B	7.15B	4.74B	3.99B
Total Debt	13.83B	15.15B	14.28B	12.75B	9.14B	9.91B
Total Liabilities	24.56B	25.82B	25.07B	22.10B	16.47B	17.08B
Stockholders Equity	6.64B	6.84B	6.87B	7.36B	6.88B	6.61B
Cash Flow
Free Cash Flow	0	2.58B	674.00M	2.24B	2.14B	334.00M
Operating Cash Flow	0	3.28B	1.31B	2.71B	2.52B	713.00M
Investing Cash Flow	0	-1.98B	-4.46B	-3.12B	-703.00M	-292.00M
Financing Cash Flow	0	-181.00M	939.00M	2.77B	-1.07B	-1.03B

Pharmarise Holdings Corp. Technical Analysis

Technical Analysis SentimentNegative

Last Price501.00

Price Trends

50DMA504.80Negative

100DMA498.50Positive

200DMA502.34Negative

Market Momentum

MACD-0.45Positive

RSI41.44Neutral

STOCH7.87Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2796, the sentiment is Negative. The current price of 501.00 is below the 20-day moving average (MA) of 505.95, below the 50-day MA of 504.80, and below the 200-day MA of 502.34, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 41.44 is Neutral, neither overbought nor oversold. The STOCH value of 7.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2796.

Pharmarise Holdings Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

JP:2796 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:219A	71Outperform	JPY 69.13B	-102.83	―	―	―	―
JP:4931	71Outperform	JPY 42.81B	12.86	―	2.85%	3.38%	32.41%
JP:2796	61Neutral	JPY 5.89B	59.01	―	2.79%	7.64%	―
JP:4350	57Neutral	JPY 16.87B	18.82	―	2.15%	8.19%	-25.81%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
JP:3417	52Neutral	JPY 13.41B	17.70	―	3.09%	2.87%	-73.55%
JP:190A	32Underperform	JPY 3.79B	-2.48	―	―	―	24.21%

* General Sector Average

Performance Comparison

JP:2796 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:2796	Pharmarise Holdings Corp.	501.00	-10.24	-2.00%
JP:3417	Ohki Health Care Holdings, Inc.	972.00	-403.75	-29.35%
JP:4350	Medical System Network Co., Ltd.	559.00	78.00	16.22%
JP:4931	Shinnihonseiyaku Co., Ltd.	2000.00	-101.69	-4.84%
JP:190A	Chordia Therapeutics Inc.	49.00	-62.00	-55.86%
JP:219A	Heartseed, Inc.	3015.00	1272.00	72.98%

Pharmarise Holdings Corp. Corporate Events

Pharmarise Posts Q1 Loss But Maintains Full-Year Forecasts and Dividend Plan

Sep 17, 2026

Pharmarise Holdings reported consolidated net sales of ¥17,242 million for the three months ended August 31, 2026, up 2.9% year on year, but operating profit fell 54.8% to ¥68 million and ordinary profit dropped 31.3% to ¥79 million. T...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 26, 2026

Pharmarise Holdings Corp. AI Stock Analysis